Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28736093 | 0.83 | CYP19A1 (0.48) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL29592190 | 0.83 | CYP19A1 (0.48) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL23219086 | 0.78 | TBXAS1 (0.43) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL28736139 | 0.76 | TBXAS1 (0.53) | CYP11B1CYP11B2CYP19A1TBXAS1BRD4 | |
| SCHEMBL29592780 | 0.73 | PTPN1 (0.31) | — | |
| SCHEMBL23218980 | 0.73 | PTPN1 (0.31) | — | |
| SCHEMBL9843977 | 0.73 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL9844130 | 0.73 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 | |
| SCHEMBL23218208 | 0.72 | ALDH1A1 (0.42) | POLBKDM4ELMNAMAPTTDP1 | |
| Hydrochloric Acid SCHEMBL9844241 | 0.72 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP19A1CYP17A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | CYP11B1 1811/4885CYP11B2 1368/4885CYP19A1 3834/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CYP11B1 1854/4885CYP11B2 1922/4885CYP19A1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.